Print

Sunovion Pharmaceuticals Inc. Announces Upcoming Availability of ZETONNA™ (ciclesonide) Nasal Aerosol, a Non-Aqueous, Dry Nasal Aerosol Spray for Allergic Rhinitis  
5/7/2012 9:34:59 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced the upcoming availability of ZETONNA™ (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA Nasal Aerosol is the first and only non-aqueous, dry nasal aerosol spray with one spray per nostril (37 mcg) and once-daily dosing, and is indicated for the treatment of both ocular and nasal symptoms associated with seasonal allergic rhinitis (SAR) and the treatment of nasal symptoms associated with perennial allergic rhinitis (PAR). It also features an easy-to-read, built-in dose indicator so patients can track when their prescriptions should be refilled. ZETONNA was approved by the U.S. Food and Drug Administration (FDA) in January 2012.
//-->